A practical reference on aggregation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-15. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
=== Electron shells === The Danish physicist Niels Bohr applied Max Planck's idea of quantization to the atom. He concluded that the energy levels of electrons were quantised: only a discrete set of stable energy states were allowed. Bohr then attempted to understand periodicity through electron configurations, surmising in 1913 that the outer electrons should be responsible for the chemical properties of the element. In 1913, he produced the first electronic periodic table based on a quantum atom. Bohr called his electron shells "rings" in 1913: atomic orbitals within shells did not exist at the time of his planetary model. Bohr explains in Part 3 of his famous 1913 paper that the maximum electrons in a shell is eight, writing, "We see, further, that a ring of n electrons cannot rotate in a single ring round a nucleus of charge ne unless n < 8." For smaller atoms, the electron shells would be filled as follows: "rings of electrons will only join if they contain equal numbers of electrons; and that accordingly the numbers of electrons on inner rings will only be 2, 4, 8." However, in larger atoms the innermost shell would contain eight electrons: "on the other hand, the periodic system of the elements strongly suggests that already in neon N = 10 an inner ring of eight electrons will occur." His proposed electron configurations for the atoms (shown to the right) mostly do not accord with those now known. They were improved further after the work of Arnold Sommerfeld and Edmund Stoner discovered more quantum numbers.
=== Thin film deposition === Vacuum evaporation is also a form of physical vapor deposition used in the semiconductor, microelectronics, and optical industries. In this context it is used to deposit thin films of material onto surfaces. Such a technique consists of pumping a vacuum chamber to low pressures (<10−5 torr) and heating a material to produce vapor to deposit the material onto a cold surface. The material to be vaporized is typically heated until its vapor pressure is high enough to produce a flux of several Angstroms per second by using an electrically resistive heater or bombardment by a high voltage beam.
== Awards and honours == 1936 Fellow of the Royal Society of Canada 1946 Order of the British Empire 1962 Honorary member of the Canadian Public Health Association (CPHA) 1964 Banting Medal of the American Diabetes Association 1967 Canada Gairdner International Award 1971 Honorary doctor of the University of Toronto 1971 Charles H. Best Prize
Sources: en.wikipedia.org
== External links == The MEROPS online database for peptidases and their inhibitors: S01.223 Acrosin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) This article incorporates text from the United States National Library of Medicine, which is in the public domain.
A third form can sometimes be encountered in which the spaces below yttrium in group 3 are left empty, such as the table appearing on the IUPAC web site, but this creates an inconsistency with quantum mechanics by making the f-block 15 elements wide (La–Lu and Ac–Lr) even though only 14 electrons can fit in an f-subshell. There is moreover some confusion in the literature on which elements are then implied to be in group 3. While the 2021 IUPAC report noted that 15-element-wide f-blocks are supported by some practitioners of a specialized branch of relativistic quantum mechanics focusing on the properties of superheavy elements, the project's opinion was that such interest-dependent concerns should not have any bearing on how the periodic table is presented to "the general chemical and scientific community". Other authors focusing on superheavy elements since clarified that the "15th entry of the f-block represents the first slot of the d-block which is left vacant to indicate the place of the f-block inserts", which would imply that this form still has lutetium and lawrencium (the 15th entries in question) as d-block elements in group 3. Indeed, when IUPAC publications expand the table to 32 columns, they make this clear and place lutetium and lawrencium under yttrium in group 3. Several arguments in favour of Sc-Y-La-Ac can be encountered in the literature, but they have been challenged as being logically inconsistent.
=== Disability === Emotional mental disorders are a leading cause of disabilities worldwide. Investigating the degree and severity of untreated emotional mental disorders throughout the world is a top priority of the World Mental Health (WMH) survey initiative, which was created in 1998 by the World Health Organization (WHO). "Neuropsychiatric disorders are the leading causes of disability worldwide, accounting for 37% of all healthy life years lost through disease. These disorders are most destructive to low and middle-income countries due to their inability to provide their citizens with proper aid. Despite modern treatment and rehabilitation for emotional mental health disorders, "even economically advantaged societies have competing priorities and budgetary constraints".
Sources: en.wikipedia.org
VEGFR-2 inhibitor, also known as kinase insert domain receptor(KDR) inhibitor, are tyrosine kinase receptor inhibitors that reduce angiogenesis or lymphangiogenesis, leading to anticancer activity. Generally they are small, synthesised molecules that bind competitively to the ATP-site of the tyrosine kinase domain. VEGFR-2 selective inhibitor can interrupt multiple signaling pathways involved in tumor, including proliferation, metastasis and angiogenesis.
=== Underreporting in men === Men often do not report a personal issue of BED. Underreporting could be a result of measurement bias due to how eating disorders are defined. The current definition for eating disorders focuses on thinness. However, eating disorders in men tend to center on muscularity and would therefore warrant a need for a different measurement definition. Overvaluation rates of body weight or shape in adolescent males are significantly lower than their female counterparts (4.9% and 24.2%, respectively). Little is known if this discrepancy is an indicator of later onset of body image distortion in males or a consequence of female-centric diagnostic frameworks for eating disorders. The lack of representation of men in eating disorder research has been hindered by historical perceptions of eating disorders as a "female phenomenon". Researchers have been called on to address this gap by advancing methods of "identification, assessment, classification, and treatment" for eating disorders in a male-specific context, specifically in young men.
==== Dietary iron uptake ==== The absorption of dietary iron is a variable and dynamic process. The amount of iron absorbed compared to the amount ingested is typically low, but may range from 5% to as much as 35% depending on circumstances and type of iron. The efficiency with which iron is absorbed varies depending on the source. Generally, the best-absorbed forms of iron come from animal products. Absorption of dietary iron in iron salt form (as in most supplements) varies somewhat according to the body's need for iron, and is usually between 10% and 20% of iron intake. Absorption of iron from animal products, and some plant products, is in the form of heme iron, and is more efficient, allowing absorption of from 15% to 35% of intake. Heme iron in animals is from blood and heme-containing proteins in meat and mitochondria, whereas in plants, heme iron is present in mitochondria in all cells that use oxygen for respiration. Like most mineral nutrients, the majority of the iron absorbed from digested food or supplements is absorbed in the duodenum by enterocytes of the duodenal lining. These cells have special molecules that allow them to move iron into the body. To be absorbed, dietary iron can be absorbed as part of a protein such as heme protein or iron must be in its ferrous Fe2+ form. A ferric reductase enzyme on the enterocytes' brush border, duodenal cytochrome B (Dcytb), reduces ferric Fe3+ to Fe2+.
The Buran could be fitted with four Saturn AL-31 turbofan engines and a fuel tank in its payload bay, allowing it to make its own atmospheric test flights, which began in November 1985. Also unlike the US Shuttle, it could be flown pilotlessly and landed automatically. Energia-Buran made only one orbital test flight in November 1988, but US counterintelligence baited the Soviets with disinformation about the heat shield design, and it was not reusable for repeated flight. Buran was the largest and most expensive Soviet program in the history of the Space Race, and was effectively canceled by the collapse of the Soviet Union in 1991, due to lack of funding. The Energia was also canceled at the same time, after only two flights.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.